Shanghai, China
Duality Biologics, established in 2020, is a cutting-edge, clinical-stage biotech company headquartered in China. With the ambition encapsulated in its slogan, "To Become A Global ADC Powerhouse," the company is at the forefront of developing next-generation Antibody-Drug Conjugate (ADC) therapies to combat cancer and autoimmune diseases.
Duality Biologics has developed a robust pipeline with four advanced clinical assets and over ten innovative candidates in the preclinical phase. This impressive portfolio stems from their proprietary ADC technology platforms, showcasing global intellectual property rights. Their commitment to pioneering "super ADC" molecules, including bispecific and dual payload ADCs, further solidifies their innovative edge.
The most recent financial milestone was an investment of $213.00 million through an IPO on April 1, 2025. Duality Biologics presents a promising investment opportunity in the biotech industry, positioning itself as a prospective leader in global ADC therapeutics development.
